Researchers from South Australia's University of Adelaide and the Queen Elizabeth Hospital are planning on injecting common cold virus along witha their DNA-based vaccine into the immune system of a laboratory mice.
 
 Branka Grubor-Bauk from the University of Adelaide said the team targeted the vaccine into areas in which the HIV infection is most commonly found, and discovered that the testing achieved a "significant reduction" of infection rates in the mice.
 
 "You need to get protection where your body encounters the virus first and you need to stop that virus from either entering, or you need to stop it from replicating and stop it from spreading,we are hoping our discovery is definitely pointing us in the right direction” Bauk commented on the success of the test conducted. 
 
 The next series of tests to ascertain the success of the vaccine will be on humans but only after through additional tests are conducted to minimise any amount of side affects of the vaccination on humans. 
 
"After four years of studies, we were able to create this common cold virus that encoded proteins of HIV and we vaccinated mice and we have been  successful in creating immunity in mucosal surfaces," Grubor-Bauk said.
 
 "We also have a DNA vaccine we administered in the epidermal area, like the influenza vaccine, and we found that by administering this vaccine we were able to get a systemic immunity throughout the whole body."
 
 The results of the testing were published in the Scientific Reports journal.